ID | 31972 |
JaLCDOI | |
フルテキストURL | |
著者 |
Ishida, Makoto
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Murakami, Kazuharu
Tamashima Central Hospital
Sakurai, Masaru
Tamashima Central Hospital
|
抄録 | It is well known that antecedent term delivery and metastasis to sites other than the lungs and vagina are high risk factors for patients with gestational trophoblastic neoplasia. Here we report on a patient with choriocarcinoma who presented with brain and lung metastases after term delivery and was treated by EMA-CO chemotherapy. A 31-year-old woman delivered a healthy infant at term. Frequent episodes of hemoptysis occurred beginning 3 weeks after the delivery. On admission to our hospital, she had lesions in the uterus, lungs and brain as well as motor aphasia and hemiplagia. The pretreatment beta-hCG level was 21,000 ng/ml and the WHO score was 16 (high-risk group). The EMA-CO regimen was administrated as first-line chemotherapy and the patient achieved complete remission after 7 courses. Treatment was terminated after 11 courses and maintained with etoposide (25 mg/day) for 6 months. The patient has remained in complete remission for more than 16 years without other adjuvant therapies. We believe that EMA-CO can currently be considered the regimen of first choice for most high-risk patients with gestational trophoblastic neoplasia in view of its effectiveness and excellent tolerability. |
キーワード | choriocarcinoma
term delivery
EMA-CO chemotherapy
metastasis
|
Amo Type | Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2005-10
|
巻 | 59巻
|
号 | 5号
|
出版者 | Okayama University Medical School
|
開始ページ | 253
|
終了ページ | 258
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |